File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

TitleThe preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
Authors
Ma, BBYSung, FTao, QPoon, FFLui, VWYeo, WChan, SLChan, ATC
KeywordsHepatitis B
Hepatocellular carcinoma
PXD101
Tumor suppressor genes
Issue Date2010
Citation
Investigational New Drugs, 2010, v. 28 n. 2, p. 107-114 How to Cite?
DOI: http://dx.doi.org/10.1007/s10637-009-9219-7
AbstractThe activity of the histone deacetylase inhibitor PXD101 was investigated in three hepatocellular carcinoma (HCC) cell lines. PXD101was found to inhibit cell growth at a dose-dependent manner and induce histone acetylation in PLC/PRF/5, Hep3B and HepG2 cells. In PLC/PRF/5 and Hep3B cells which express hepatitis B-related genes (HBx, HBc and HBc), treatment with PXD101 resulted in apoptosis without a significant effect on viral gene expression. Exposure to PXD101 for up to 48 h had varying effects on the expression of 12 cellular genes with tumor suppressor functions, including p21, SOCS1, CMTM5, RASAL1, DLEC1, SFRP (-1, -2, -4 and -5), ADAMTS (-8 and -9). This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC. © 2009 Springer Science+Business Media, LLC.
Persistent Identifierhttp://hdl.handle.net/10722/194271
ISSN
0167-6997
2021 Impact Factor: 3.651
2020 SCImago Journal Rankings: 1.254
ISI Accession Number ID
WOS:000275208300001

 

DC FieldValueLanguage
dc.contributor.authorMa, BBY-
dc.contributor.authorSung, F-
dc.contributor.authorTao, Q-
dc.contributor.authorPoon, FF-
dc.contributor.authorLui, VW-
dc.contributor.authorYeo, W-
dc.contributor.authorChan, SL-
dc.contributor.authorChan, ATC-
dc.date.accessioned2014-01-30T03:32:23Z-
dc.date.available2014-01-30T03:32:23Z-
dc.date.issued2010-
dc.identifier.citationInvestigational New Drugs, 2010, v. 28 n. 2, p. 107-114-
dc.identifier.issn0167-6997-
dc.identifier.urihttp://hdl.handle.net/10722/194271-
dc.description.abstractThe activity of the histone deacetylase inhibitor PXD101 was investigated in three hepatocellular carcinoma (HCC) cell lines. PXD101was found to inhibit cell growth at a dose-dependent manner and induce histone acetylation in PLC/PRF/5, Hep3B and HepG2 cells. In PLC/PRF/5 and Hep3B cells which express hepatitis B-related genes (HBx, HBc and HBc), treatment with PXD101 resulted in apoptosis without a significant effect on viral gene expression. Exposure to PXD101 for up to 48 h had varying effects on the expression of 12 cellular genes with tumor suppressor functions, including p21, SOCS1, CMTM5, RASAL1, DLEC1, SFRP (-1, -2, -4 and -5), ADAMTS (-8 and -9). This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC. © 2009 Springer Science+Business Media, LLC.-
dc.languageeng-
dc.relation.ispartofInvestigational New Drugs-
dc.subjectHepatitis B-
dc.subjectHepatocellular carcinoma-
dc.subjectPXD101-
dc.subjectTumor suppressor genes-
dc.titleThe preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s10637-009-9219-7-
dc.identifier.pmid19172229-
dc.identifier.scopuseid_2-s2.0-77952240320-
dc.identifier.volume28-
dc.identifier.issue2-
dc.identifier.spage107-
dc.identifier.epage114-
dc.identifier.isiWOS:000275208300001-
dc.identifier.issnl0167-6997-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats